Pyxis Oncology, Inc. (NASDAQ:PYXS) to Post FY2023 Earnings of ($2.05) Per Share, Leerink Partnrs Forecasts

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Leerink Partnrs issued their FY2023 EPS estimates for shares of Pyxis Oncology in a note issued to investors on Tuesday, January 23rd. Leerink Partnrs analyst J. La. Rosa forecasts that the company will post earnings per share of ($2.05) for the year. Leerink Partnrs has a "Outperform" rating on the stock. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.92) per share. Leerink Partnrs also issued estimates for Pyxis Oncology's Q4 2023 earnings at ($0.54) EPS, Q1 2024 earnings at ($0.32) EPS, Q2 2024 earnings at ($0.31) EPS, Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings at ($1.19) EPS, Q1 2025 earnings at ($0.41) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.23) EPS, FY2026 earnings at ($1.14) EPS, FY2027 earnings at ($1.13) EPS and FY2028 earnings at ($1.09) EPS.

A number of other brokerages also recently issued reports on PYXS. William Blair restated an "outperform" rating on shares of Pyxis Oncology in a research report on Wednesday, November 8th. SVB Leerink initiated coverage on shares of Pyxis Oncology in a research report on Tuesday. They issued an "outperform" rating and a $12.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $4.00 price target on shares of Pyxis Oncology in a research report on Thursday, November 30th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $9.25.

Pyxis Oncology Price Performance

NASDAQ:PYXS opened at $3.14 on Thursday. The firm's 50 day simple moving average is $1.89 and its 200 day simple moving average is $2.03. Pyxis Oncology has a one year low of $1.35 and a one year high of $6.92. The company has a market cap of $139.16 million, a PE ratio of -1.23 and a beta of 1.09.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its earnings results on Tuesday, November 7th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.01.

Institutional Trading of Pyxis Oncology

Several hedge funds have recently modified their holdings of PYXS. Credit Suisse AG bought a new stake in shares of Pyxis Oncology in the 2nd quarter valued at $2,298,000. Decheng Capital Management III Cayman LLC bought a new stake in shares of Pyxis Oncology in the 3rd quarter valued at $650,000. Citigroup Inc. increased its stake in shares of Pyxis Oncology by 7,171.6% in the 1st quarter. Citigroup Inc. now owns 233,129 shares of the company's stock valued at $942,000 after acquiring an additional 229,923 shares in the last quarter. ExodusPoint Capital Management LP increased its stake in shares of Pyxis Oncology by 270.8% in the 2nd quarter. ExodusPoint Capital Management LP now owns 259,561 shares of the company's stock valued at $664,000 after acquiring an additional 189,561 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Pyxis Oncology by 168.8% in the 2nd quarter. Renaissance Technologies LLC now owns 253,229 shares of the company's stock valued at $648,000 after acquiring an additional 159,029 shares in the last quarter. Institutional investors own 52.53% of the company's stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.